Muscle-invasive bladder cancer represents approximately 25% of diagnosed bladder cancer cases and carries a significant risk of death. Oncolytic viruses are novel antitumor agents with the ability to selectively replicate and lyse tumor cells while sparing healthy tissue. We explored the efficiency of the oncolytic YB-1-selective adenovirus XVir-N-31 in vitro and in an orthotopic mouse model for bladder cancer by intramural injection under ultrasound guidance. We demonstrated that XVir-N-31 replicated in bladder cancer cells and induced a stronger immunogenic cell death than wild-type adenovirus by facilitating enhanced release of HMGB1 and exosomal Hsp70. The intratumoral delivery of XVir-N-31 by ultrasound guidance delayed tumor growth in an immunodeficient model, demonstrating the feasibility of this approach to deliver oncolytic viruses directly into the tumor.
Get full access to this article
View all access options for this article.
References
1.
FerlayJ, SoerjomataramI, DikshitR, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 136:E359–386.
2.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2016. CA Cancer J Clin, 2016; 66:7–30.
3.
WitjesJA, LebretT, ComperatEM, et al.Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol, 2017; 71:462–475.
4.
HautmannRE, de PetriconiRC, PfeifferC, et al.Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol, 2012; 61:1039–1047.
LichtyBD, BreitbachCJ, StojdlDF, et al.Going viral with cancer immunotherapy. Nat Rev Cancer, 2014; 14:559–567.
7.
WorkenheST, MossmanKL. Oncolytic virotherapy and immunogenic cancer cell death: Sharpening the sword for improved cancer treatment strategies. Mol Ther, 2014; 22:251–256.
8.
De MunckJ, BinksA, McNeishIA, et al.Oncolytic virus-induced cell death and immunity: a match made in heaven?. J Leukoc Biol, 2017; 102:631–643.
9.
GuoZS, LiuZ, BartlettDL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol, 2014; 4:74.
10.
KroemerG, GalluzziL, KeppO, et al.Immunogenic cell death in cancer therapy. Annu Rev Immunol, 2013; 31:51–72.
11.
FendL, YamazakiT, RemyC, et al.Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res, 2017; 77:4146–4157.
12.
RibasA, DummerR, PuzanovI, et al.Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 2017; 170:1109–1119.e1110.
13.
ChesneyJ, PuzanovI, CollichioF, et al.Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 2017:Jco2017737379.
14.
FarinaMS, LundgrenKT, BellmuntJ. Immunotherapy in urothelial cancer: recent results and future perspectives. Drugs, 2017; 77:1077–1089.
15.
GuptaS, GillD, PooleA, et al.Systemic immunotherapy for urothelial cancer: current trends and future directions. Cancers (Basel), 2017; 9(2):pii: E15.
16.
RognoniE, WidmaierM, HaczekC, et al.Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. Cancer Gene Ther, 2009; 16:753–763.
17.
KosnopfelC, SinnbergT, SchittekB. Y-box binding protein 1—a prognostic marker and target in tumour therapy. Eur J Cell Biol, 2014; 93:61–70.
18.
LashamA, PrintCG, WoolleyAG, et al.YB-1: oncoprotein, prognostic marker and therapeutic target?. The Biochemical journal, 2013; 449:11–23.
19.
ShiotaM, YokomizoA, ItsumiM, et al.Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU Int, 2011; 108:E142–149.
20.
SongYH, ShiotaM, YokomizoA, et al.Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. Urol Oncol, 2014; 32:31.e31–37.
21.
HolmPS, BergmannS, JurchottK, et al.YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem, 2002; 277:10427–10434.
22.
MantwillK, NaumannU, SeznecJ, et al.YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med, 2013; 11:216.
HadaschikBA, ZhangK, SoAI, et al.[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer]. Der Urologe Ausg A, 2008; 47:1145–1151.
25.
JagerW, MoskalevI, JanssenC, et al.Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PloS One, 2013; 8:e59536.
26.
BettAJ, HaddaraW, PrevecL, et al.An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A, 1994; 91:8802–8806.
27.
MantwillK, Kohler-VargasN, BernshausenA, et al.Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res, 2006; 66:7195–7202.
28.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods, 2001; 25:402–408.
29.
TheryC, AmigorenaS, RaposoG, et al.Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, 2006;Chapter 3:Unit 3 22.
30.
HohlA, RammsAS, DohmenC, et al.Adenovirus particle quantification in cell lysates using light scattering. Hum Gene Ther Methods, 2017; 28:268–276.
31.
BergelsonJM, CunninghamJA, DroguettG, et al.Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science, 1997; 275:1320–1323.
32.
DmitrievI, KrasnykhV, MillerCR, et al.An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol, 1998; 72:9706–9713.
33.
SudarshanS, HolmanDH, HyerML, et al.In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther, 2005; 12:12–18.
34.
GargAD, GalluzziL, ApetohL, et al.Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol, 2015; 6:588.
35.
ScaffidiP, MisteliT, BianchiME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 2002; 418:191–195.
36.
FucikovaJ, KralikovaP, FialovaA, et al.Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res, 2011; 71:4821–4833.
37.
KawanoM, TanakaK, ItonagaI, et al.Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett, 2016; 11:2169–2175.
38.
ErdbruggerU, LanniganJ. Analytical challenges of extracellular vesicle detection: a comparison of different techniques. Cytometry A, 2016; 89:123–134.
39.
PolJ, BuquéA, ArandaFet al.Trial watch—oncolytic viruses and cancer therapy. Oncoimmunology, 2016; 5:e1117740.
40.
PottsKG, HittMM, MooreRB. Oncolytic viruses in the treatment of bladder cancer. Adv Urol, 2012; 2012:404581.
41.
BurkeJM, LammDL, MengMV, et al.A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol, 2012; 188:2391–2397.
42.
PackiamVT, CampanileAN, BarocasDA, et al.A phase II/III trial of CG0070, an oncolytic adenovirus, for BCG-refractory non-muscle-invasive bladder cancer (NMIBC). J Urol, 2016; 195(4S):e142.
43.
GomellaLG, MastrangeloMJ, McCuePA, et al.Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol, 2001; 166:1291–1295.
44.
ItoH, AokiH, KuhnelF, et al.Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst, 2006; 98:625–636.
45.
Rodriguez-RochaH, Garcia-GarciaA, PanayiotidisMI, et al.DNA damage and autophagy. Mutat Res, 2011; 711:158–166.
46.
TazawaH, KurodaS, HaseiJ, et al.Impact of autophagy in oncolytic adenoviral therapy for cancer. Int J Mol Sci, 2017; 18(7). pii: E1479.
47.
YouL, MaoL, WeiJ, et al.The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses. J Hematol Oncol, 2017; 10:165.
48.
DiaconuI, CerulloV, HirvinenML, et al.Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res, 2012; 72:2327–2338.
49.
ApetohL, GhiringhelliF, TesniereA, et al.Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007; 13:1050–1059.
50.
BasuS, BinderR, RamalingamT, et al.CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 2001; 14:303–313.
51.
NevinsJR. Induction of the synthesis of a 70,000 dalton mammalian heat shock protein by the adenovirus E1A gene product. Cell, 1982; 29:913–919.
RadonsJ, MulthoffG. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev, 2005; 11:17–33.
54.
WangJ, SunX, ZhaoJ, et al.Exosomes: a novel strategy for treatment and prevention of diseases. Front Pharmacol, 2017; 8:300.
55.
DingJ, XuD, PanC, et al.Current animal models of bladder cancer: awareness of translatability (review). Exp Ther Med, 2014; 8:691–699.
56.
KleijnA, van den BosscheW, HaefnerES, et al.The sequence of delta24-RGD and TMZ administration in malignant glioma affects the role of CD8(+)T cell anti-tumor activity. Mol Ther Oncolytics, 2017; 5:11–19.
57.
TysomeJR, LiX, WangS, et al.A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res, 2012; 18:6679–6689.
58.
WojtonJ, KaurB. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev, 2010; 21:127–134.
59.
BielerA, MantwillK, HolzmullerR, et al.Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother Oncol, 2008; 86:419–427.
60.
YahataH, KobayashiH, KamuraT, et al.Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol, 2002; 128:621–626.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
